Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Papillary renal cell carcinoma, sporadic 1Hereditary leiomyomatosis and renal cell cancer 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 11pembrolizumab 8enfortumab vedotin 8Specimen Handling 8Cisplatin 8Magnetic Resonance Spectroscopy 6avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Biopsy 3cabozantinib 2Standard of Care 2Ramucirumab 2Platinum 2Ipilimumab 2Immunoglobulin G 2Doxorubicin 2Docetaxel 2Disulfides 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Contrast Media × Genitourinary × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡